Ozempic, Wegovy, Mounjaro and alcohol: can they be taken together?

Short answer: Moderate alcohol consumption is not a problem for most people taking GLP-1 medicines such as Ozempic, Wegovy, Mounjaro and Saxenda, but the combination may increase nausea and requires extra caution if you are taking other diabetes medicines or have a history of pancreatitis.

Many users of GLP-1 medicines find that they react differently to alcohol: with a reduced appetite, feeling fuller more quickly, or, conversely, experiencing more side effects after just a few sips. This is no coincidence. GLP-1 medicines such as Ozempic, Wegovy, Mounjaro and Saxenda affect the same systems that also determine how your body processes alcohol.

In this blog, we’ll go through what is known about the combination of GLP-1 medicines and alcohol, and what you need to be aware of. We’ll discuss semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) and liraglutide (Saxenda) individually, where relevant.

How do GLP-1 medicines affect your alcohol tolerance?

GLP-1 medicines slow down gastric emptying and enhance the feeling of fullness, and this effect isn’t limited to solid food. As the stomach empties more slowly, the alcohol also reaches the small intestine more slowly, where it is absorbed into the bloodstream. In theory, this delays the rate at which blood alcohol concentration rises, but it can also mean that the alcohol remains in the stomach for longer and has a stimulating effect before it is absorbed.

When consumed on an empty stomach, the effect is less predictable: some users report, on the contrary, that the alcohol has a stronger effect. This mechanism, how GLP-1 medicines delay gastric emptying, underlies both the satiety effect and this altered response to alcohol. There is still a lack of controlled studies on the precise impact on the blood alcohol curve in humans, so caution is advised.

Do GLP-1 medicines reduce the craving for alcohol?

There is a growing body of scientific research investigating whether GLP-1 agonists can reduce the craving for alcohol. A review of GLP-1 receptor agonists as a potential treatment for alcohol misuse shows that these medicines affect the brain’s reward system in the same way as they suppress the urge to eat. This may occur via the dopamine pathway, which also plays a role in addictive behaviour. A recent systematic review of GLP-1 receptor agonists and alcohol misuse confirms that the initial results are promising, although the number of large clinical trials in humans remains limited.

Other research into the role of GLP-1 in addiction susceptibility emphasises that the effect extends beyond mere eating behaviour. Important: This is experimental research. GLP-1 medicines are not authorised in the Netherlands as a treatment for alcohol dependence, and a reduction in cravings must never be used to justify excessive alcohol consumption.

What are the risks of drinking alcohol whilst on GLP-1 treatment?

The main practical risk is an exacerbation of existing GLP-1 side effects. Alcohol irritates the stomach lining, and as the medication already slows gastric emptying, the combination can worsen nausea, vomiting and other gastrointestinal symptoms. This is consistent with the common side effects of GLP-1 medicines, which already occur in some users, even without alcohol. Furthermore, vomiting caused by alcohol, combined with reduced fluid intake, can lead to dehydration more quickly than in users who do not take GLP-1 medicines.

For people with type 2 diabetes who, in addition to semaglutide or tirzepatide, also use insulin or a sulphonylurea, there is an increased risk of hypoglycaemia (low blood sugar): alcohol can inhibit the liver’s production of glucose, thereby amplifying the effect of blood-sugar-lowering medicines. In practice, this is a well-known point to be aware of in this group, even though the patient information leaflet does not explicitly mention alcohol as a risk factor.

Is there a difference between the various medicines (Ozempic, Wegovy, Mounjaro, Saxenda)?

Semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) and liraglutide (Saxenda) work on the same basic principle. They mimic a hormone produced naturally by the body that is released after a meal. In this way, they help to keep blood sugar levels under control, curb appetite and ensure that the stomach empties more slowly. Tirzepatide also works in another way, which may enhance the effect on your feeling of fullness and possibly also on your craving for alcohol. The practical difference lies mainly in how long they remain active in the body. Semaglutide and tirzepatide are effective for around a week, whilst liraglutide is effective for only about half a day. Consequently, you need to inject Saxenda daily, whilst injections of the other two are only required once a week.

None of the official package leaflets in the Farmacotherapeutisch Kompas explicitly mention alcohol as an interaction or contraindication. The advice in this blog is therefore general precautionary advice based on the mechanism of action, not an official warning in the package leaflet. If you’d like to compare the options side by side, we’ve compiled an overview of Ozempic, Wegovy, Mounjaro and Saxenda side by side.

How much alcohol is safe to drink whilst on GLP-1 treatment?

For most users not taking diabetes medication, there is no specific contraindication against moderate alcohol consumption. The general advice is to follow the Dutch guidelines: no more than one glass a day, preferably with several alcohol-free days a week. According to the Farmacotherapeutisch Kompas, this advice on moderation applies in all circumstances to the general population, regardless of GLP-1 use.

There is no reason to assume that users of Wegovy, Mounjaro or Saxenda should systematically deviate from this. However, it is wise to exercise extra caution if you are already suffering from nausea, vomiting or bloating due to the medication: in such cases, alcohol may further exacerbate these symptoms.

When is alcohol not recommended whilst using GLP-1?

If you have a history of pancreatitis, it is particularly important to exercise caution with alcohol. Acute pancreatitis is a rare but serious potential side effect of semaglutide, tirzepatide and liraglutide, and a history of pancreatitis is considered a relative contraindication for all three. Irrespective of this, alcohol is a recognised risk factor for pancreatitis, and when two independent risk factors occur simultaneously, the overall risk increases.

It is also advisable to exercise restraint with alcohol if you have existing liver problems, as the drugs are metabolised by the liver. If, in addition to semaglutide or tirzepatide, you are also using insulin or a sulphonylurea for type 2 diabetes, it is wise to limit your alcohol intake and keep a close eye on your blood sugar levels due to the increased risk of hypoglycaemia. If you are unsure whether your situation falls into one of these categories, you should discuss this with your doctor or healthcare professional before drinking alcohol.

Alcohol and GLP-1 medicines: in moderation and with caution

For most GLP-1 users, moderate alcohol consumption is not a problem, but it does require awareness of side effects and specific risk groups, such as people taking diabetes medication or with a history of pancreatitis. Goodweigh discusses this as standard during the initial consultation and throughout the coaching programme, so you know what to be aware of in your particular situation.